Jul. 28 at 11:39 AM
$KNSA Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of
$0.33 up 37.50% YoY
• Reported revenue of
$243.6M up 55.36% YoY
• Kiniksa Pharmaceuticals expects 2026 ARCALYST net product revenue to be between
$980 million and
$995 million, raised from prior guidance of between
$930 million and
$945 million for the fiscal year.
